OPKO Health, Inc. OPK Cash Flow

Opko health, inc. (OPK)

CashFlow / Yearly

Dec'19	Dec'18	Dec'17	Dec'16	Dec'15	Dec'14	Dec'13	Dec'12	Dec'11	Dec'10	Dec'09
Cash flows from operating activities:
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
-314,925	-153,040	-305,250	-48,359	-31,428	-174,638	-117,346	-29,540	-1,283	-18,926	-30,113
Income from discontinued operations, net of tax
-	-	-	-	-	-	-	-	5,181	-6,250	-5,722
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization
93,807	97,344	102,093	96,576	42,248	14,927	15,216	10,160	3,830	2,207	564
Non-cash interest
8,731	4,903	2,575	2,699	2,612	5,662	5,980	0	2	-	-
Amortization of Debt Issuance Costs
995	187	224	237	1,212	2,007	1,170	0	0	-	-
Income (Loss) from Equity Method Investments, Net of Tax
-2,900	-14,497	-14,471	-	-	-	-	-	-	-	-
Income (Loss) from Equity Method Investments
-	-	-	-7,652	-7,105	-3,587	-11,456	-2,062	-1,589	-714	-353
Accretion of debt discount related to notes payable
-	-	-	-	-	-	-	-	-	66	123
Equity-based compensation – employees and non-employees
13,400	21,800	28,300	42,700	26,074	14,779	10,983	5,131	6,953	6,519	4,174
Realized loss on disposal of fixed assets and sales of equity securities
-739	-46	8,663	-2,321	-7,091	-167	29,881	0	0	-	-
Impairment of intangible assets
-	-	-	-	0	-	-	-	-	-	-
Provision for bad debts
-	-	-	-	-	-	979	-95	257	-89	-25
Provision for inventory obsolescence
-	-	-	-	-	-	2,015	2,688	607	-48	-137
Revenue from receipt of equity
-	-	-	-	140	240	12,740	159	85	731	-
Loss (gain) on conversion of 3.00% convertible senior notes
-	-	-	-284	943	2,668	972	0	0	-	-
Loss (gain) on disposal of fixed assets
-	-	-	-	-	-	-60	0	0	-	-
Change in fair value of equity securities and derivative instruments
-8,748	6,524	52	2,778	-39,083	-10,632	-45,942	1,218	-39	-	-
In-process research and development
-	-	-	-	-	12,055	0	0	-	-	2,000
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability
-14,854	-16,816	-3,423	16,954	5,050	24,446	6,947	785	0	-	-
Asset Impairment Charges
92,400	21,778	13,194	0	-	-	-	-	-	-	-
Gain on deconsolidation of SciVac
-	-	-	-	15,940	0	0	-	-	-	-
Deferred income tax (benefit) provision
4,324	-35,133	16,092	-66,300	-123,536	1,017	599	-9,958	-19,749	-348	-
Changes in assets and liabilities, net of the effects of acquisitions:
Accounts receivable, net
-7,376	-20,397	-58,011	25,637	4,845	3,273	-754	-763	1,719	2,888	740
Inventory, net
12,133	-4,590	3,539	6,607	4,953	670	-1,892	5,807	-2,170	8,156	636
Other current assets and prepaid expenses
11,486	-2,276	-4,771	-17,262	4,391	-3,182	1,131	2,877	-57	-270	-432
Other assets
-409	69	2,372	1,899	305	3,378	544	361	-16	-13	58
Accounts payable
15,636	-26,083	20,171	-19,819	-18,122	-3,852	1,829	1,247	-1,784	1,498	-547
Foreign currency measurement
-71	294	-255	-376	979	945	-2,386	-86	-363	-	-
Contract liabilities
-69,302	-61,264	-58,876	-50,893	-	-	-	-	-	-	-
Deferred revenue
-	-	-	-	227,671	0	0	-	-	-	-
Accrued expenses and other liabilities
764	1,715	30,441	68,036	9,502	4,934	3,525	1,678	-21	-3,510	-829
Cash used in operating activities of continuing operations
-	-	-	-	-	-	-	-	-13,939	-17,159	-19,393
Cash provided by operating activities of discontinued operations
-	-	-	-	-	-	-	-	-4,561	-1,553	-4,065
Net cash used in operating activities
-172,522	-109,141	-92,080	32,046	164,024	-90,379	-55,653	-25,415	-18,500	-18,712	-23,458
Cash flows from investing activities:
Investments in investees
1,200	1,000	9,625	14,424	4,375	589	17,441	3,396	2,013	650	4,800
Proceeds from sale of equity securities
0	1,516	2,211	0	0	-1,331	-30,556	0	0	-	-
Acquisition of businesses, net of cash acquired
-	-	-	-15,878	79,000	1,683	-20,528	19,092	28,186	1,323	15,632
Acquisition of intangible assets
-	-	-	5,000	5,000	0	0	-	-	-	-
Acquisition of rolapitant
-	-	-	-	-	-	-	-	-	-	2,000
Purchase of marketable securities
-	-	-	15,644	0	0	50,027	25,806	100,161	14,997	9,997
Maturities of short-term marketable securities
-	-	-	15,634	0	0	50,027	24,997	100,161	14,997	9,997
Proceeds from the sale of property, plant and equipment
671	1,223	7,271	1,401	0	0	636	0	0	-	-
Capital expenditures
12,741	27,858	46,524	18,547	10,846	4,734	3,962	1,472	1,953	774	122
Cash provided (or used) by investing activities from continuing operations
-	-	-	-	-	-	-	-	-32,152	-2,747	-22,554
Cash provided by investing activities from discontinued operations
-	-	-	-	-	-	-	-	17,316	-33	-50
Net cash used in investing activities
-13,270	-26,119	-46,667	-20,702	-99,221	-5,675	30,317	-24,769	-14,836	-2,780	-22,604
Cash flows from financing activities:
Issuance of common stock
76,062	92,500	0	0	-	-	-	-	104,828	-	50,990
Issuance of 2033 Senior Notes, including to related parties
200,293	55,000	0	0	-	-	170,184	0	0	-	-
Debt issuance costs
7,762	0	0	-	-	-	-	-	-	-	-
Proceeds from the exercise of Common Stock options and warrants
-3	1,173	2,132	8,576	25,921	12,928	23,425	2,279	1,244	74	718
Purchase of Common Stock held in treasury
-	-	-	-	-	-	-	-	7,832	-	-
Redemption of Series A Preferred Stock (including related parties
-	-	-	-	-	-	-	-	1,792	-	-
Payment of Series D dividends, including related parties
-	-	-	-	-	-	3,015	0	4,704	-	-
Issuance of Series D preferred stock and warrants, including related parties
-	-	-	-	-	-	-	-	-	-	30,000
Repayments of line of credit with related party
-	-	-	-	-	-	-	-	-	12,000	-
Proceeds from bridge loan with related party
-	-	-	-	-	-	-	-	-	-	3,000
Repayment of bridge loan with related party
-	-	-	-	-	-	-	-	-	-	3,000
Cash from non-controlling interest
-	-	-	-	100	2,696	0	0	-	-	-
Contingent consideration payments
-	-	-	-	-	6,435	2,539	0	-	-	-
Borrowings on lines of credit
294,780	26,917	92,421	22,407	261,339	26,443	34,577	36,506	15,300	15,424	529
Repayments of Lines of Credit
359,322	34,681	33,510	66,178	254,355	28,369	38,997	32,754	20,127	-	-
Redemption of 2033 Senior Notes
28,800	0	0	-	-	-	-	-	-	-	-
Repayments of lines of credit and capital lease obligations
-	-	-	-	-	-	-	-	-	6,266	317
Net cash (used in) provided by financing activities
175,248	140,909	61,043	-35,195	33,005	7,263	183,635	6,031	86,917	-2,768	81,920
Effect of exchange rate changes on cash and cash equivalents
-477	-675	470	-1,014	-1,117	-100	138	-2	-81	-382	122
Net increase (decrease) in cash and cash equivalents
-11,021	4,974	-77,234	-24,865	96,691	-88,891	158,437	-44,155	53,500	-24,642	35,980
SUPPLEMENTAL INFORMATION:
Interest paid
11,873	2,076	1,313	2,890	4,572	6,276	3,407	945	-	-	-
Income taxes paid, net of refunds
2,667	-1,410	5,416	-27,122	4,879	954	1,321	575	-	-	-
Operating lease right-of-use assets due to adoption of ASU No. 2016-02
39,380	0	0	-	-	-	-	-	-	-	-
Operating lease liabilities due to adoption of ASU No. 2016-02
39,703	0	0	-	-	-	-	-	-	-	-
RXi common stock received
-	-	-	-	-	-	12,500	0	-	-	-
Pharmsynthez common stock received
-	-	-	-	-	6,264	0	0	-	-	-
Non-cash financing:
Shares issued upon the conversion of:
Common Stock options and warrants, surrendered in net exercise
20	806	1,546	350	14,369	3,494	815	7	-	-	-
Issuance of capital stock to acquire or contingent consideration settlement:
2033 Senior Notes
Shares issued upon the conversion of - 2033 Senior Notes
-	-	-	583	-	-	-	-	-	-	-
Transition Therapeutics, Inc.
Capital stock issued
-	-	-	58,530	-	-	-	-	-	-	-
OPKO Renal
Capital stock issued
-	-	-	25,986	-	-	-	-	-	-	-
OPKO Health Europe
Capital stock issued
0	0	304	313	-	-	-	-	-	-	-
Xenetic Biosciences, Inc. [Member]
Capital stock issued
-	-	-	4,856	-	-	-	-	-	-	-